| On Thursday 28 January: |
| 16:00 - 16:10 |
Welcome and introduction
|
| 16:10 - 16:40 |
An overview of current vaccine platforms and the development of a new vaccine against SARS-CoV-2 Johan Neyts, Rega Institute, KU Leuven, Belgium Q&A
|
| 16:40 - 17:10 |
The challenges of setting up a Phase 1 vaccine trial during the Corona pandemic: The sponsor’s point of view Johan Van Hoof, Janssen Pharmaceutica, Beerse, Belgium Q&A
|
| 17:10 - 17:30 |
The challenges of conducting a Phase 1 vaccine trial during the Corona pandemic: The investigator’s point of view Wouter Botermans, Center for Clinical Pharmacology, KU Leuven, Belgium Q&A
|
| 17:30 - 17:40 |
General Discussion
|
| 17:40 - 18:00 |
Closing remarks
|